The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Update from SOHO 2020 on follicular lymphoma

Sep 30, 2020

During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the Lymphoma Hub was pleased to speak to Steering Committee member Nathan Fowler, MD Anderson Cancer Center, Houston, US. In this interview he provided an update on follicular lymphoma from the SOHO 2020 Meeting.

Update from SOHO 2020 on follicular lymphoma

Nathan Fowler first outlines the recent advances in the management of patients with newly diagnosed indolent lymphoma. He highlights the superiority in progression-free survival observed in patients receiving obinutuzumab + chemotherapy over rituximab + chemotherapy. He also discusses the results from the RELEVANCE trial, evaluating lenalidomide + rituximab vs rituximab + chemotherapy.

In the relapsed setting, several novel agents have been approved by the FDA in recent years, including PI3K inhibitors, lenalidomide in combination with rituximab, and the first-in-class EZH2 inhibitor, tazemetostat.

Your opinion matters

At this year’s virtual ESH Meeting, the Lymphoma Hub Satellite Symposium will evaluate treatment options in patients with R/R DLBCL. What do you think is the most promising emerging therapy in this setting?
4 vote s - 16 hours left ...


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox every month